StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for NAGE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $3.78 | $3.80 | +0.53% | 0.8M |
| 05-15 | $3.74 | $3.65 | -2.41% | 1.4M |
| 05-18 | $3.64 | $3.70 | +1.65% | 0.8M |
| 05-19 | $3.70 | $3.67 | -0.81% | 0.7M |
| 05-20 | $3.66 | $3.75 | +2.46% | 0.8M |
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $31.47M | $129.42M | $95.58M | $61.60M |
Operating Income | $1.58M | $16.28M | $12.19M | $7.96M |
Net Income | $6.32M | $17.38M | $13.25M | $8.67M |
EPS (Diluted) | $0.07 | $0.20 | $0.15 | $0.10 |
Total Assets | $114.33M | $106.41M | $98.14M | $91.53M |
Total Liabilities | $32.00M | $29.87M | $27.46M | $27.33M |
Cash & Equivalents | $66.55M | $64.79M | $64.10M | $60.30M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 79.46M | 79.71M | 79.64M | 79.59M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.